ANTIVIRICOS-BICTEGRAVIR+EMTRICITABINA + TENOFOVIR ALAFENAMIDA - 3MESES
TED · 616442-2026Award noticeawardedNo deadline given
Buyer
NameServiços de Saúde da Região Autónoma da Madeira, EPERAM (SESARAM; EPERAM)
CountryPT
Published2026-09-08
Deadline—
Who already wins at this buyer
Firms with recorded awards from Serviços de Saúde da Região Autónoma da Madeira, EPERAM (SESARAM; EPERAM) in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| JANSSEN CILAG FARMACEUTICA, LDA | 5 | — | 2026-10-02 |
| MERCK SHARP & DOHME,LDA -MSD | 5 | — | 2026-09-25 |
| ASTRAZENECA PRODUTOS FARMACEUTICOS, LDA | 2 | — | 2026-09-08 |
| GRIFOLS PORTUGAL LDA | 2 | — | 2026-10-16 |
| NOVO NORDISK PORTUGAL, LDA | 1 | €225,776 | 2026-08-19 |
CPV codes
33690000 Medical equipment & pharmaceuticalsDescription
ANTIVIRICOS-BICTEGRAVIR+EMTRICITABINA + TENOFOVIR ALAFENAMIDA - 3MESES
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-07-28 | 2024/0900 - BICTEGRAVIR + EMTRICITABINA + TENOFOVIR ALAFENAMIDA [50 + 200 + 25 MG CÁP/ COMP] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 94% |
| 2026-08-11 | 2024/0900 - EMTRICITABINA + RILPIVIRINA + TENOFOVIR ALAFENAMIDA [200 + 25 + 25 MG COMP] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 93% |
| 2026-09-22 | 2024/0900 - EMTRICITABINA + TENOFOVIR ALAFENAMIDA [200 + 25 MG COMP] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 92% |
| 2026-09-15 | 2024/0900 - DARUNAVIR + COBICISTATE + EMTRICITABINA + TENOFOVIR ALAFENAMIDA [800 + 150 + 200 + 10 MG COMP] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 92% |
| 2026-10-15 | AD/2827/2026 Aquisição de Bictegravir 50 mg + Emtricitabina 200 mg + Tenofovir alafenamida 25 mg, para a ULSTMAD, EPE | Unidade Local de Saúde de Trás-os-Montes e Alto Douro, EPE PT | 92% |
| 2026-10-13 | 2024/0900 - EMTRICITABINA + RILPIVIRINA + TENOFOVIR [200 MG + 25 MG + 245 MG CÁP/COMP] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 92% |